期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他汀类药物,从心血管疾病到肾脏病 被引量：10

Statins,From Cardiovascular Disease to Kidney Disease
下载PDF
导出
摘要 随着他汀类药物在临床上的广泛应用,其降脂和各种降脂外作用能在很大程度上减少心血管事件发生的风险;同时,人们也对他汀类药物在慢性肾脏疾病中的肾保护作用产生了浓厚的兴趣,开展了一系列的试验研究来揭示他汀类药物的多效性,现就此做一综述。 Widely used in patients, statins have been found to be effective drugs in reducing cholesterol and cardiovascular morbidity and mortality. Meanwhile, the renoprotective effect of statins has generated increasing interest in the treatment of chronic kidney diseases with statins. Research studies have been carried out which reveal the ＂pleiotropic＂ effects of statins.
作者 李振勇 倪兆慧
机构地区 上海交通大学医学院附属仁济医院肾脏科
出处 《心血管病学进展》 CAS 2007年第5期802-805,共4页 Advances in Cardiovascular Diseases
关键词 他汀类药物 心血管疾病 慢性肾脏病 statins cardiovascular disease chronic kidney disease
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献24

  • 1Rogler G,Lackner KJ,Schmitz G.Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro[J].Am J Cardiol,1995,76:114A-116A.
  • 2Park YS,Guijarro C,Kim Y,et al.Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats[J].Am J Kidney Dis,1998,31:190-194.
  • 3Yoshida M,Sawada T,Ishii H,et al.HMG-CoA reductase inhibitor modulatesmonocyte-endothelial cell interaction under physiological flow conditions invitro:involvement of Rho GTPase-dependent mechanism[J].ArteriosclerThromb Vasc Biol,2001,21:1165-1171.
  • 4Wassmann S,Laufs U,Muller K,et al.Cellular antioxidant effects of atorvastatin in vitro and in vivo[J].Arterioscler Thromb Vasc Biol,2002,22:300-305.
  • 5Laufs U,La Fata V,Plutzky J,et al.Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors[J].Circulation,1998,97:1129-1135.
  • 6Hernandez-Perera O,Perez-Sala D,Navarro-Antolin J,et al.Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors,atorvastatin and simvastatin,on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells[J].J Clin Invest,1998,101:2711-2719.
  • 7Hernandez-Perera O,Perez-Sala D,Soria E,et al.Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells[J].Circ Res,2000,87:616-622.
  • 8Sukhova GK,Williams JK,Libby P.Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol[J].Arterioscler Thromb Vasc Biol,2002,22:1452-1458.
  • 9Kizu A,Shioi A,Jono S,et al.Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators[J].J Cell Biochem,2004,93(5):1011-1019.
  • 10Son BK,Kozaki K,Iijima K,et al.Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway[J].Circ Res,2006,98:1024.

二级参考文献15

  • 1Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes:a randomised placebo-controlled trial[J]. Lancet ,2003,361:2005-2016.
  • 2Sever PS,Dahlof B, Poulter NR,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) : a multicenter randomized controlled trial[J]. Lancet,2003,361:1149-1158.
  • 3Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention[J]. Circulation ,2003,107:363-369.
  • 4Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med,2002,347:1557-1565.
  • 5Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14,719 initially healthy Americau women[J]. Circulation,2003,107:391-397.
  • 6Ridker PM, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein[ J]. Circulation, 1999,100:230-235.
  • 7Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation(PRINCE) :a randomized trial and cohort study[J]. JAMA,2001,286:64-70.
  • 8Strandberg TE,Vanhanen H,Tikkanen M J, Association between change in C-reactive protein and serum lipids during statin treatment[J]. Ann Med,2000,32 :579-583.
  • 9van Wissert S, Trip MD, Smilde TJ, et al. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy [J]. Atherosclerosis ,2002,165:361-366.
  • 10Ridker PM ,Rifai N ,Pfeffer MA ,et al. Inflammation ,pravastatin ,and the risk of coronary events after myocardial infarction in patients with average cholesterol levels[J]. Circulation, 1998,98:839-844.

共引文献39

同被引文献57

引证文献10

二级引证文献54

心血管病学进展
2007年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部